And your vosoritide question, as far as data triggers for next regulatory interactions and the big one is going to be the pivotal results of the Phase 3 trial. The three other pillars of the program study in children under five, the long-term extension study that we're going to give you 54-month data as well as its comparison to natural history data. Those three elements are necessary but not sufficient and the next meaningful milestone to occur in the [Indecipherable] program is going to be the unblinding of the Phase 3 program at the end of the year.